Author: OurCrowd

[ReWalk in GlobeNewswire] ReWalk Robotics appoints Michael Lawless as Chief Financial Officer

Sep 8, 2022 |

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 08, 2022 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) (the “Company” or “ReWalk”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced the appointment of Michael Lawless, CPA, as Chief Financial Officer, effective September 19, 2022. Mr. Lawless brings more than 20 years of experience leading finance and investor relations activities at life science and technology companies to drive greater financial discipline, better strategic decision making, and improved access to capital. Read more...

Read More

[Taranis in PR Newswire] Taranis raises $40 million Series D to advance crop intelligence and unlock growth opportunities for agribusinesses

Sep 7, 2022 | ,

WESTFIELD, Ind. and TEL AVIV, Israel, Sept. 7, 2022 /PRNewswire/ — Taranis, the leading AI-powered crop intelligence provider, announced today that it has raised $40 million in Series D funding. The round was led by Inven Capital, a European climate tech fund, with participation from new investors Seraphim Space Investment Trust (‘SSIT’) and Farglory Group, and strong backing from existing investors: Vertex Growth, Viola Ventures, Vertex Ventures Israel, La Maison Partners, Hitachi Ventures, K3 Ventures, UMC Capital, OurCrowd, Micron Ventures, iAngels Ventures, Presidio Ventures (Sumitomo), Cavallo Ventures (Wilbur Ellis), Finistere Ventures, and Eyal Gura. This latest round brings Taranis’ total funding to $100 million. Read...

Read More

[Medisafe in PR Newswire] Medisafe enhances pharma digital vision with latest ISO certification

Sep 7, 2022 |

BOSTON, Sept. 7, 2022 /PRNewswire/ — Medisafe, the leading medication engagement company, today announced that it has achieved the ISO 13485:2016 certification which supports the design and development of Software as a Medical Device (SaMD) used for the diagnosis, prognosis, or prediction of disease progression. Achieving this new certification serves as third-party industry validation that Medisafe continues to enhance its offering in support of pharma’s vision for a more integrated and digitally enhanced future. Read...

Read More